Since 2015, Dr. Toren has worked as a clinician-scientist in the Department of Surgery at Laval University, where his laboratory focuses on translational prostate cancer research. He completed his medical training at Queen’s University in Kingston, Ontario, urology residency and a clinical uro-oncology fellowship at the University of Toronto. Subsequently, he completed a two-year research fellowship at the Vancouver Prostate Centre, under the mentorship of Dr. Martin Gleave. Concurrently, he enrolled in, and recently completed a doctorate in experimental medicine in Dr. Amina Zoubeidi’s laboratory.

The influence of sex steroids on the tumor environment

Androgens and estrogens are important to prostate cancer progression and treatment resistance. Through the analysis of various sex steroids such as testosterone and estrogens, we seek to better understand the hormonal changes which occur following treatment in prostate cancer patients. Further, we seek to understand how differences in these levels between patients may be used to classify them for optimal treatments and understand resistance patterns. We use laboratory models to understand the effect of sex steroids on the local immune environment and production of cytokines regulating the survival and growth of prostate cancer.

Extracellular vesicles as biomarkers

Extracellular vesicles, such as exosomes, are tiny parts of cells which may be detected in many biological fluids, including urine and blood. Using samples from prostate cancer patients, we seek to optimize isolation, enumeration, and characterization techniques. Versatile and containing a significant amount of information pertinent to cancer type and function, these tiny particles may eventually be used to monitor information about responsiveness to treatments through a simple blood test.

Hôpital de l'Enfant-Jésus
1401, 18e rue
G4.610
Québec, QC
Canada G1J 1Z4
60 entries « 1 of 6 »

Turcotte B, Bélanger L, Blais AS, Blouin AC, Bolduc S, Bolduc-Mokhtar A, Bureau M, Caumartin Y, Cloutier J, Deschênes-Rompré MP, Dujardin T, Fradet Y, Gaudreau N, Lacombe L, Moore K, Morin F, Nadeau G, Paquet S, Simard F, Simonyan D, Soucy F, Tiguert R, Toren P, Lodde M, Pouliot F

Perception and satisfaction of patients after telemedicine urology consultations: A matched analysis with physicians' perspective

Journal Article

Can Urol Assoc J, 2022.

Abstract | Links:

Berrehail Z, Boibessot C, Gris T, Joncas FH, Gaignier F, Guillemette C, Lacombe L, Fradet Y, Toren P

Sex steroid modulation of macrophages within the prostate tumor microenvironment

Journal Article

Am J Clin Exp Urol, 10 (2), 2022.

Abstract | Links:

Turcotte B, Jacques E, Tremblay S, Toren P, Caumartin Y, Lodde M

Opioids use after uro-oncologic surgeries in time of opioid crisis

Journal Article

Can Urol Assoc J, 2022.

Abstract | Links:

Fadel J, Akoum N, Lodde M, Toren P

Case - Gigantic obstructive calculi in continent urinary diversion

Journal Article

Can Urol Assoc J, 2022.

| Links:

Fradet S, Pelletier JF, Singbo N, Lacombe L, Toren P, Lodde M, Dujardin T, Tiguert R, Fradet Y, Robitaille K, Fradet V

Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy

Journal Article

Clin Nutr ESPEN, 47 , 2022.

Abstract | Links:

Boibessot C, Molina O, Lachance G, Tav C, Champagne A, Neveu B, Pelletier JF, Pouliot F, Fradet V, Bilodeau S, Fradet Y, Bergeron A, Toren P

Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype

Journal Article

Clin Transl Med, 12 (1), 2022.

Abstract | Links:

Kourbanhoussen K, Joncas FH, D Wallis CJ, Hovington H, Dagenais F, Fradet Y, Guillemette C, Lacombe L, Toren P

Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer

Journal Article

Asian J Androl, 24 (1), 2022.

Abstract | Links:

Tremblay S, Summers-Trasiewicz L, Pouliot F, Crook JM, Ding K, Klotz L, Toren P

Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer

Journal Article

J Urol, 206 (5), 2021.

Abstract | Links:

Boibessot C, Joncas FH, Park A, Berrehail Z, Pelletier JF, Gris T, Bergeron A, Toren P

Using ex vivo culture to assess dynamic phenotype changes in human prostate macrophages following exposure to therapeutic drugs

Journal Article

Sci Rep, 11 (1), 2021.

Abstract | Links:

Tremblay S, Summers-Trasiewicz L, Pouliot F, Crook JM, Ding K, Klotz L, Toren P

Reply by Authors

Journal Article

J Urol, 206 (5), 2021.

| Links:

60 entries « 1 of 6 »
Signaler des ajouts ou des modifications

Active projects

  • A study of macrophages as predictors of prostate cancer radiotherapy response , from 2022-01-26 to 2023-01-25
  • Targeting sex steroids to improve the response to bladder cancer immunotherapy, from 2021-10-01 to 2026-09-30

Recently finished projects

  • (FRSQ 91289) Androgen-receptor dependent changes in human bladder cancer macrophages.” , from 2019-09-04 to 2021-09-03
  • Development of next-generation biomarkers for prostate cancer treatment, from 2019-07-01 to 2021-12-31
  • Investiguer les facteurs moléculaires qui influencent la progression du cancer de la prostate., from 2016-07-01 to 2020-06-30
  • Sex steroids as modulators of the prostate cancer immune microenvironment, from 2018-09-01 to 2021-08-31
Data provided by the Université Laval research projects registery